Inventor
BOYLE CRAIG D
US28 patents
⚠️ This page may combine multiple inventors who share the name “BOYLE CRAIG D”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SCHERING CORP
17 patentsUS6821978B2Nov 23, 2004
Xanthine phosphodiesterase V inhibitors
SCHERING CORP140 citations99
US5889006AMar 30, 1999
Muscarinic antagonists
SCHERING CORP123 citations97
US6630475B2Oct 7, 2003
Adenosine A2a receptor antagonists
SCHERING CORP53 citations95
US6043255AMar 28, 2000
Muscarinic antagonists
SCHERING CORP50 citations95
US6897217B2May 24, 2005
2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
SCHERING CORP25 citations92
US6444687B1Sep 3, 2002
Substituted imidazole neuropeptide Y Y5 receptor antagonists
SCHERING CORP18 citations92
US6916811B2Jul 12, 2005
Adenosine A2a receptor antagonists
SCHERING CORP17 citations83
US6890936B2May 10, 2005
Muscarinic antagonists
SCHERING CORP9 citations74
US6632828B2Oct 14, 2003
Substituted imidazole neuropeptide Y Y5 receptor antagonists
SCHERING CORP6 citations74
US6897216B2May 24, 2005
Adenosine A2a receptor antagonists
SCHERING CORP5 citations73
US7572802B2Aug 11, 2009
7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-C]-pyrimidin-5-amine
SCHERING CORP7 citations71
US7531544B2May 12, 2009
Xanthine phosphodiesterase V inhibitors
SCHERING CORP2 citations63
US7709492B2May 4, 2010
Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
SCHERING CORP2 citations62
US7465740B2Dec 16, 2008
2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
SCHERING CORP3 citations62
US7368449B2May 6, 2008
2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
SCHERING CORP4 citations62
US7312223B2Dec 25, 2007
Metabolite of xanthine Phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
SCHERING CORP3 citations59
US7192962B2Mar 20, 2007
Xanthine phosphodiesterase V inhibitor polymorphs
SCHERING CORP5 citations55
BOYLE CRAIG D
5 patentsUS8318751B2Nov 27, 2012
Pyrimidinone derivatives and methods of use thereof
BOYLE CRAIG D3 citations60
US8389532B2Mar 5, 2013
7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-E]-[1,2,4]-triazolo-[1,5-C]-pyrimidin-5-amine
BOYLE CRAIG D2 citations59
US9301929B2Apr 5, 2016
Substituted biaryl derivatives and methods of use thereof
BOYLE CRAIG D0 citations49
US8580807B2Nov 12, 2013
Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders
BOYLE CRAIG D2 citations49
US8466149B2Jun 18, 2013
6-substituted sulfonyl azabicyclo[3.2.1]octanes useful to inhibit 11β-hydroxysteroid dehydrogenase type-I
BOYLE CRAIG D0 citations38